Bayer Orion focus on tolerability of darolutamide as they look to challenge Erleada Xtandi in prostate cancer httpswww.firstwordpharma.comnode1625399Â $BAY GU19

Bayer, Orion focus on tolerability of darolutamide as they look to challenge Erleada, Xtandi in prostate cancer https://www.firstwordpharma.com/node/1625399  $BAY #GU19

06:08 EST 15 Feb 2019 | FirstWord Pharma

Bayer, Orion focus on tolerability of darolutamide as they look to challenge Erleada, Xtandi in prostate cancer https://www.firstwordpharma.com/node/1625399  $BAY #GU19

More From BioPortfolio on "Bayer, Orion focus on tolerability of darolutamide as they look to challenge Erleada, Xtandi in prostate cancer https://www.firstwordpharma.com/node/1625399  $BAY #GU19"